Biotechnology entrepreneur and executive, Dr. Shawn Iadonato, has a distinguished career as a founder and C-level executive (CEO, COO, CSO) for both public and private biotech companies. He has extensive experience in founding, funding, and building innovative businesses with groundbreaking technologies.
Overdose from illicit fentanyl is the leading cause of death for working-age Americans. CounterX Therapeutics is committed to ending the fentanyl overdose epidemic and offering hope to individuals, families and communities devastated by this crisis. CounterX Therapeutics is developing CTRX-101, a once-monthly treatment that blocks fentanyl's lethal effects and prevents overdose. Supported by over $40M in NIH funding, we are positioned to address a critical public health crisis with a potential market of ~3.1M patients and peak-year sales of $4.6B.
